Innoviva Specialty Therapeutics, Inc. (IST), a wholly-owned subsidiary of Innoviva, Inc. announced that Patricia Drake has been appointed as Chief Commercial Officer. In her new role, she will play a key role in shaping the company's commercial strategy and driving growth of the company's commercial portfolio of infectious disease and critical care products, which include XACDURO (sulbactam-durlobactam), XERAVA (eravacycline) and GIAPREZA (angiotensin II). Ms. Drake is a highly accomplished life science leader who brings unique experience and achievements to Innoviva Specialty Therapeutics.

Her strong leadership background, encompassing strategy, marketing, market access, sales, and commercial operations, is a testament to her capabilities. During her 32-year tenure at Merck, she successfully led commercial organizations across diverse global markets and product portfolios, which included antiviral, oncology, antifungal, and antibiotic products and multiple global business units spanning North and South America and the Nordics. Before joining Innoviva Specialty Therapeutics, Ms. Drake served as the SVP and Chief Commercial Officer at the biopharmaceutical company, Trevena, Inc. She also held significant leadership roles with various global healthcare companies, including CEO and Managing Director of MSD Finland, Global Human Health Strategy Officer at Merck Co., and the business unit leader for hospital and specialty business in Merck Canada.